Emerging Nonfactor Approaches for Patients with Hemophilia: Enhancing and Rebalancing Therapies

Target Audience
This educational activity is intended for HCPs who care for patients with hemophilia, including hematologists and advanced practice professionals (nurse practitioners and physician assistants).

Program Overview
This interactive learning module is a self-directed educational activity, led by experts Dr. Michelle Sholzberg and Dr. Angela Weyand. Topics include new and emerging treatments, novel agents that are being developed, current clinical studies and potential concerns of novel therapies.

Learning Objectives
Upon completion of this activity, participants should be able to:

Describe how novel agents for patients with hemophilia, including those targeting antithrombin, FVIIIa, and tissue factor pathway inhibitor (TFPI) are being developed to enhance and rebalance the hemostatic system
Summarize current clinical studies of these novel therapies for hemophilia
Outline potential concerns regarding these novel therapies